Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Zynteglo Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Zynteglo (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    CareSource Arkansas PASSE medical prior authorization coverage for Zynteglo, a one-time gene therapy for eligible adult and pediatric members with beta-thalassemia; continued therapy is not authorized.

    Policy Summary
    PayerCareSource
    PolicyZynteglo (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia
    Policy CodePolicy N/A
    Change TypeMaterial clinical and coverage update
    Effective DateOct 1, 2026
    Last ReviewMar 2, 2026
    Next Review DateN/A
    Key ActionSubmit genetic testing results confirming beta-thalassemia with the prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a requirement for genetic confirmation of the beta-thalassemia diagnosis.

    The policy references were updated on March 2, 2026.

    89%Transfusion independence in pivotal studies
    ≥4 years; ≥6 kgMinimum age and weight
    100 mL/kg/yearMinimum transfusion volume
    ≥8/yearAlternative transfusion frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial authorization period
    80 mL (4 bags)Quantity limit

    Coverage Criteria

    Initial Therapy

    Covered for initial authorization when all criteria below are met, including the exclusion criteria in the following block. If approved, authorization is for 6 months.

    ALL of the following

    • Member is at least 4 years of age and weighs at least 6 kg.
    • Medication is prescribed by or in consultation with a hematologist or transplant specialist.
    • Member has a diagnosis of β-thalassemia confirmed by genetic testing results.
    • Member meets at least ONE transfusion-dependence criterion

      • Required at least 100 mL/kg/year of packed red blood cells (pRBCs) in each of the last 2 years.
      • Required at least 8 pRBC transfusions per year in each of the last 2 years.
    • Member is clinically stable and a suitable candidate for allogeneic hematopoietic stem cell transplantation (HSCT), but does not have an available and willing human leukocyte antigen (HLA)-matched sibling or family donor.
    • Member tested negative for hepatitis B, hepatitis C, HIV, and human T-lymphotrophic virus 1 and 2 (HTLV-1/HTLV-2) before cell collection.
    • Dosage and quantity limits are met: minimum 5.0 × 10^6 CD34+ cells/kg and a maximum of 80 mL (4 bags).

    Initial therapy is not covered when any of the following apply: prior or current malignancy; prior HSCT; prior gene therapy; advanced liver disease; or cardiac T2* less than 10 ms on MRI, indicating iron overload in the heart.

    Zynteglo will not be authorized for continued therapy.

    CareSource considers Zynteglo (betibeglogene autotemcel) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, refer to the Off-Label policy.

    Clinical Thresholds and Requirements

    Minimum CD34+ Cell Dose
    Minimum dose5.0 × 10^6 CD34+ cells/kg
    Authorization contextRequired for initial authorization
    Quantity requirementThe administered dose must meet the minimum CD34+ cell requirement
    Cardiac Iron Overload Exclusion
    Exclusion thresholdCardiac T2* <10 ms on MRI
    Clinical significanceIndicates iron overload in the heart
    Coverage requirementThe member must not have cardiac T2* <10 ms on MRI

    Provider Action Required

    Prior Authorization

    Obtain medical prior authorization

    Medical prior authorization is required for Zynteglo. When all policy criteria are met, initial authorization is available for 6 months.

    Documentation Required

    Submit required clinical documentation

    Submit documentation supporting the initial authorization request, including genetic testing confirming beta-thalassemia, pRBC transfusion dependence over the last 2 years, pre-cell-collection infection testing, and cardiac T2* MRI results.

    • Genetic testing results confirming beta-thalassemia
    • Documentation of pRBC transfusion dependence over the last 2 years
    • Negative hepatitis B, hepatitis C, HIV, and HTLV-1/HTLV-2 results before cell collection
    • Cardiac T2* MRI results

    Therapy Background

    Zynteglo (betibeglogene autotemcel) is an autologous hematopoietic stem cell-based gene therapy administered as a one-time intravenous infusion. The member’s CD34+ stem cells are collected and genetically modified ex vivo to encode a functional modified beta-globin gene before being reinfused. Beta-thalassemia results from HBB gene mutations that reduce or eliminate functional adult hemoglobin production, causing ineffective erythropoiesis, microcytic anemia, iron overload, and possible lifelong dependence on red blood cell transfusions.

    Key Definitions

    Transfusion Independence
    DefinitionNo longer requiring red blood cell transfusions
    Minimum durationFor at least 12 months
    Hemoglobin requirementMaintaining an average hemoglobin level of at least 9
    Transfusion Dependence
    DefinitionRequiring packed red blood cell transfusions at the specified volume or frequency
    Volume thresholdAt least 100 mL/kg/year of packed red blood cells in the last 2 years
    Frequency thresholdAt least 8 packed red blood cell transfusions per year in the last 2 years

    Initial Therapy Authorization

    Initial Authorization Criteria

    Initial authorization is covered only when all listed requirements are met.

    Initial authorization requirements

    • Eligibility and prescribing: The member is at least 4 years of age and weighs at least 6 kg; the medication is prescribed by or in consultation with a hematologist or transplant specialist; and beta-thalassemia is confirmed by genetic testing results.Age ≥4 years; weight ≥6 kg
    • Transfusion dependence: The member has required at least 100 mL/kg/year of pRBCs in the last 2 years or at least 8 pRBC transfusions per year in the last 2 years.≥100 mL/kg/year OR ≥8 transfusions per year in each of the last 2 years

    Continuation and Reauthorization

    No Reauthorization

    Continued therapy is not authorized.

    Continuation therapy: Zynteglo will not be authorized for continued therapy because it is a one-time treatment.

    Quantity and Dose Limits

    Zynteglo Quantity Limits
    Quantity limit80 mL
    Number of bags4 bags
    Minimum dose5.0 × 10^6 CD34+ cells/kg
    Treatment courseOne-time treatment
    Policy Summary
    PayerCareSource
    PolicyZynteglo (betibeglogene autotemcel) for transfusion-dependent beta-thalassemia
    Policy CodePolicy N/A
    Change TypeMaterial clinical and coverage update
    Effective DateOct 1, 2026
    Last ReviewMar 2, 2026
    Next Review DateN/A
    Key ActionSubmit genetic testing results confirming beta-thalassemia with the prior authorization request.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and RequirementsProvider Action RequiredTherapy BackgroundKey DefinitionsInitial Therapy AuthorizationContinuation and ReauthorizationQuantity and Dose Limits
    pRBC Transfusion Volume
    Minimum volumeAt least 100 mL/kg/year of packed red blood cells
    Lookback periodIn each of the last 2 years
    Qualification pathwayMeets the transfusion-dependence criterion when either the volume or frequency threshold is satisfied
    pRBC Transfusion Frequency
    Minimum frequencyAt least 8 packed red blood cell transfusions per year
    Lookback periodIn each of the last 2 years
    Alternative criterionThis is an alternative to the minimum volume requirement of 100 mL/kg/year
    Denial Risk

    Screen for disqualifying conditions

    Initial authorization may be denied if the member has any listed disqualifying condition.

    • Prior or current malignancy
    • Prior hematopoietic stem cell transplantation (HSCT)
    • Prior gene therapy
    • Advanced liver disease
    • Cardiac T2* <10 ms on MRI
    Denial Risk

    Confirm transplant candidacy and donor status

    Initial authorization may be denied unless the member is clinically stable and suitable for allogeneic HSCT and does not have an available and willing HLA-matched sibling or family donor.

    • Confirm clinical stability and suitability for allogeneic HSCT
    • Document that no available and willing HLA-matched sibling or family donor exists
    Denial Risk

    No reauthorization is available

    Do not request reauthorization for continued Zynteglo therapy. Zynteglo is not authorized for continued therapy because it is a one-time treatment.

    Denial Risk

    Refer unlisted indications

    Coverage is not medically necessary for conditions or indications not listed in the policy. Refer other indications to the Off-Label policy.

    Transplant candidacy:
    The member is clinically stable and a suitable candidate for allogeneic HSCT but does not have an available and willing HLA-matched sibling or family donor.
  1. Infection screening: The member has tested negative for hepatitis B, hepatitis C, HIV, and HTLV-1/HTLV-2 before cell collection.Negative results before cell collection
  2. No disqualifying conditions: The member does not have prior or current malignancy, prior HSCT, prior gene therapy, advanced liver disease, or cardiac T2* <10 ms on MRI.Cardiac T2* ≥10 ms
  3. Dose and quantity: The administered dose meets the minimum CD34+ cell requirement and does not exceed the quantity limit.Minimum 5.0 × 10^6 CD34+ cells/kg; limit 80 mL (4 bags)